BioCardia, Inc. (BCDA)

Market Cap	15.41M
Revenue (ttm)	570,000
Net Income (ttm)	-12.53M
Shares Out	21.62M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,330
Open	0.643
Previous Close	0.660
Day's Range	0.639 - 0.680
52-Week Range	0.360 - 2.920
Beta	1.57
Analysts	Strong Buy
Price Target	4.00 (+512.93%)
Earnings Date	Nov 8, 2023

About BCDA

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Peter A. Altman Ph.D.
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: BCDA

Financial Performance

In 2022, BioCardia's revenue was $1.35 million, an increase of 33.20% compared to the previous year's $1.02 million. Losses were -$11.91 million, -5.67% less than in 2021.

Analyst Forecast

According to one analyst, the rating for BCDA stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target

$4.0

(512.93% upside)

Analyst Consensus: Strong Buy